Sugi Predict

Sugi Predict / Compounds / SCHEMBL1108261

SCHEMBL1108261

SCHEMBL1108261

Cc1cnc2nc1-c1cccc(c1)COC/C=C/COCc1cc(ccc1N1CCN(C)CC1)N2

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 19/20 0.73
▸ TYK2 P29597 18/20 0.73
▸ FLT3 P36888 18/20 0.73
▸ JAK1 P23458 17/20 0.73
▸ JAK3 P52333 12/20 0.68
▸ CDK2 P24941 12/20 0.68
▸ CYP3A4 P08684 3/20 0.68
▸ CYP2D6 P10635 2/20 0.68
▸ CCNA2 P20248 9/20 0.61
▸ CCNA1 P78396 9/20 0.61
▸ ALK Q9UM73 1/20 0.48
▸ GAK O14976 1/20 0.48
▸ STK16 O75716 1/20 0.48
▸ STK10 O94804 1/20 0.48
▸ MAP4K4 O95819 1/20 0.48
▸ PRKCB P05771 1/20 0.48
▸ LCK P06239 1/20 0.48
▸ CSF1R P07333 1/20 0.48
▸ PDGFRB P09619 1/20 0.48
▸ NQO2 P16083 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14023949 0.87 JAK2 (0.60) JAK2TYK2FLT3JAK1JAK3
SCHEMBL1108254 0.84 JAK2 (1.00) JAK2TYK2FLT3JAK1JAK3
SCHEMBL14022847 0.82 JAK2 (0.70) JAK2TYK2FLT3JAK1JAK3
SCHEMBL1108259 0.81 JAK2 (1.00) JAK2TYK2FLT3JAK1JAK3
SCHEMBL14023904 0.80 JAK2 (0.61) JAK2TYK2FLT3JAK1JAK3
SCHEMBL14023902 0.78 JAK2 (0.63) JAK2TYK2FLT3JAK1JAK3
SCHEMBL14022999 0.77 JAK2 (0.52) JAK2TYK2FLT3JAK1JAK3
SCHEMBL1108248 0.77 JAK2 (1.00) JAK2TYK2FLT3JAK1JAK3
SCHEMBL14022824 0.76 JAK2 (0.71) JAK2TYK2FLT3JAK1JAK3
SCHEMBL21784330 0.75 JAK2 (0.60) JAK2TYK2FLT3JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11135227-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2021-10-05 — — US disclosed
EP-3854402-A1 TREATMENT OR PREVENTION OF TRANSPLANT REJECTION CTI Biopharma Corp. (US) 2021-07-28 — — EP disclosed
US-20210069199-A1 METHODS OF TREATING TRANSPLANT REJECTION SOBI, INC. 2021-03-11 — — US disclosed
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2020-03-05 — — US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 — — US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 — — US disclosed
US-9573964-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2017-02-21 — — US disclosed
US-9573964-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2017-02-21 — — US disclosed
EP-1951729-B1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS INC (US) 2014-06-25 — — EP disclosed
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS, INC. (US) 2013-07-04 — — US disclosed
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS, INC. (US) 2013-07-04 — — US disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 — — US disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 — — US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 — — US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
WO-2007058627-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD (SG) 2007-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210069199-A1 METHODS OF TREATING TRANSPLANT REJECTION JAK1, JAK2, JAK3 JAK2 2/4885TYK2 34/4885FLT3 50/4885
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885TYK2 960/4885FLT3 645/4885
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885TYK2 960/4885FLT3 645/4885
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885TYK2 960/4885FLT3 645/4885
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885TYK2 960/4885FLT3 645/4885
US-11135227-B2 Oxygen linked pyrimidine derivatives DPYD, TK2, TK1 JAK2 468/4885TYK2 960/4885FLT3 645/4885
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885TYK2 960/4885FLT3 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.